CORE
🇺🇦
make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
A Phase III randomized study comparing a chemotherapy with cisplatin and etoposide to a etoposide regimen without cisplatin for patients with extensive small-cell lung cancer
Authors
C. G. Alexopoulos
J. Amourette
+40 more
S. Bensliman
M. C. Berchier
T. Berghmans
Y. Bonduelle
D. Brohée
B. Colinet
T. Collon
Jean-Louis Corhay
A. Drowart
A. Efremidis
X. Ficheroulle
M. C. Florin
V. Giner
S. Holbrechts
G. Koumakis
F. Kroll
J.-J. Lafitte
N. Leclercq
Julie Lecomte
E. Maetz
M. Mairesse
A.-P. Meert
M. Paesmans
T. Prigogine
P. Ravez
P. Recloux
M. Richez
M. Roelandts
A. Scherpereel
J.-P. Sculier
B. Stach
F. Steenhouwer
A. Strecker
A. Tagnon
J. Thiriaux
O. Van Cutsem
P. Van Houtte
M. Vaslamatzis
P. Wackenier
C. Zacharias
Publication date
19 September 2017
Publisher
'Frontiers Media SA'
Doi
Cite
Abstract
Introduction: In a literature meta-analysis, we showed survival benefits for regimens including cisplatin [hazard ratio (HR) 0.61; 95% confidence interval (CI), 0.57-0.66] and for those including etoposide (HR 0.65; 0.61-0.69). That benefit was mainly observed when etoposide alone or in combination with cisplatin was included in the chemotherapy regimens. Our objective was to determine if chemotherapy with both drugs improves survival in comparison to a non-platinum regimen with etoposide. Methods: Extensive small-cell lung cancer patients were randomized between cisplatin-etoposide (CE) and ifosfamide + etoposide + epirubicin regimen (IVE) between 2000 and 2013. Results: 176 and 170 eligible patients were allocated to CE and IVE (315 deaths were required before analysis), respectively. Objective response rates were not significantly different: 60% with CE and 59% with IVE. No statistically significant difference in median survival and 1-year and 2-year was observed with rates of 9.6 months, 31 and 5% for CE and 10 months, 39 and 9% for IVE, respectively. HR was 0.84 (95% CI 0.68-1.05, p = 0.16). Only two prognostic factors for survival were retained in multivariate analysis: sex with HR = 0.69 (95% CI 0.49-0.97, p = 0.03) and performance status with HR = 0.53 (95% CI 0.49-0.97, p < 0.0001). After adjustment for these prognostic factors, HR for survival was 0.83 (95% CI 0.65-1.08, p = 0.17). There was more thrombopenia in the CE regimen and more leukopenia with IVE. Conclusion: Combination of CE failed to improve survival in comparison to an etoposide-containing regimen without cisplatin. Clinical Trial Registration: https://clinicaltrials.gov/ct2/show/NCT00658580?term=ELCWP+01994&rank=1, identifier NCT00658580. © 2017 Berghmans, Scherpereel, Meert, Giner, Lecomte, Lafitte, Leclercq, Paesmans and Sculier
Similar works
Full text
Available Versions
Open Repository and Bibliography - Liège
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:orbi.ulg.ac.be:2268/256071
Last time updated on 14/10/2021